- Home
- ABSI vs XOMA Comparison
ABSI vs XOMA Comparison
Compare ABSI & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- XOMA
- Stock Information
- Founded
- ABSI 2011
- XOMA 1981
- Country
- ABSI United States
- XOMA United States
- Employees
- ABSI N/A
- XOMA N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- XOMA Health Care
- Exchange
- ABSI Nasdaq
- XOMA Nasdaq
- Market Cap
- ABSI 338.0M
- XOMA 330.2M
- IPO Year
- ABSI 2021
- XOMA N/A
- Fundamental
- Price
- ABSI $2.39
- XOMA $32.47
- Analyst Decision
- ABSI Strong Buy
- XOMA Strong Buy
- Analyst Count
- ABSI 5
- XOMA 2
- Target Price
- ABSI $7.98
- XOMA $69.50
- AVG Volume (30 Days)
- ABSI 4.4M
- XOMA 57.0K
- Earning Date
- ABSI 08-12-2025
- XOMA 08-13-2025
- Dividend Yield
- ABSI N/A
- XOMA N/A
- EPS Growth
- ABSI N/A
- XOMA N/A
- EPS
- ABSI N/A
- XOMA N/A
- Revenue
- ABSI $4,138,000.00
- XOMA $44,952,000.00
- Revenue This Year
- ABSI $44.71
- XOMA $82.30
- Revenue Next Year
- ABSI $374.26
- XOMA $12.59
- P/E Ratio
- ABSI N/A
- XOMA N/A
- Revenue Growth
- ABSI 27.32
- XOMA 194.98
- 52 Week Low
- ABSI $2.01
- XOMA $18.35
- 52 Week High
- ABSI $6.33
- XOMA $35.23
- Technical
- Relative Strength Index (RSI)
- ABSI 33.33
- XOMA 61.79
- Support Level
- ABSI $2.50
- XOMA $32.60
- Resistance Level
- ABSI $2.73
- XOMA $34.60
- Average True Range (ATR)
- ABSI 0.18
- XOMA 1.82
- MACD
- ABSI -0.04
- XOMA 0.09
- Stochastic Oscillator
- ABSI 1.94
- XOMA 66.75
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.